Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Merck
Baxter
Dow

Last Updated: September 27, 2022

SEEBRI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Seebri patents expire, and when can generic versions of Seebri launch?

Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred patent family members in thirty-two countries.

The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri

A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.

  Try it Free

Drug patent expirations by year for SEEBRI
Drug Prices for SEEBRI

See drug prices for SEEBRI

Recent Clinical Trials for SEEBRI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of SaskatchewanPhase 4
Sunovion Respiratory Development Inc.Phase 1

See all SEEBRI clinical trials

US Patents and Regulatory Information for SEEBRI

SEEBRI is protected by two US patents.

Patents protecting SEEBRI

Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhaler device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SEEBRI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SEEBRI

See the table below for patents covering SEEBRI around the world.

Country Patent Number Title Estimated Expiration
Germany 60131265 See Plans and Pricing
Canada 2539041 FABRICATION DE COMPOSITIONS PHARMACEUTIQUES (DRY POWDER COMPOSITION COMPRISING A BENZODIAZEPINE FOR PULMONARY INHALATION) See Plans and Pricing
Estonia 05257 K?vade pelletite vormis farmatseutilised preparaadid kuivpulberinhalaatoritele See Plans and Pricing
Turkey 9700722 See Plans and Pricing
Luxembourg 92393 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SEEBRI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1267866 132013902141564 Italy See Plans and Pricing PRODUCT NAME: GLICOPIRRONIO BROMURO(SEEBRI BREEZHALER); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/788/001-006, 20120928
2435024 2021C/518 Belgium See Plans and Pricing PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
1267866 CA 2013 00015 Denmark See Plans and Pricing
2435025 19C1040 France See Plans and Pricing PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220
1267866 479 Finland See Plans and Pricing
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Moodys
Colorcon
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.